DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Olmsted syndrome 1 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOlmsted syndrome 1 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for olmsted syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Olmsted syndrome is a rare keratinization disorder characterised by symmetrically distributed, destructive, inflammatory palmoplantar keratoderma with periorificial keratotic plaques, most commonly due to gain-of-function mutations in the TRPV3 gene. Additional clinical features include diffuse alopecia, leukokeratosis of the oral mucosa, onychodystrophy, hyperkeratotic linear streaks, follicular hyperkeratosis and constriction of digits. As of 2013 only 43 cases had been reported in the literature. Recent studies suggest that mutations in different structural domains of TRPV3 lead to cases of varying severity, indicating a potential genotype-phenotype correlation.
One case report from 2024 describes a 63-year-old man with Olmsted syndrome who had experienced severe pain and impaired quality of life since birth. He was treated with erlotinib 100 mg once daily, which led to a dramatic improvement in both pain and quality of life. Because of side-effects the dose was reduced to 100 mg three times a week, which maintained efficacy with minimal side-effects. This is a single case, not a controlled trial.
No other drugs are reported in these abstracts. The 2024 review paper discusses potential management and treatment but does not present new clinical trial data. The evidence base for any treatment remains limited to case reports and reviews.
What is still missing are large, controlled clinical trials, standardised outcome measures for pain and skin changes, and any understanding of which patient subgroups (by specific TRPV3 mutation) might respond to which agents. Funding for such trials and for systematic patient registries is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Genetics · 2024 · 4 citations · open access
Pathogenesis and management of TRPV3-related Olmsted syndrome
AbstractOlmsted syndrome is characterized by symmetrically distributed, destructive, inflammatory palmoplantar keratoderma with periorificial keratotic plaques, most commonly due to gain-of-function mutations in the transient receptor potential vanilloid 3 (TRPV3) gene, which involves multiple pathological functions of the skin, such as hyperkeratosis, dermatitis, hair loss, itching, and pain. Recent studies suggest that mutations of TRPV3 located in different structural domains lead to cases of varying severity, suggesting a potential genotype-phenotype correlation resulting from TRPV3 gene mutations. This paper reviews the genetics and pathogenesis of Olmsted syndrome, as well as the potential management and treatment. This review will lay a foundation for further developing the individualized treatment for TRPV3-related Olmsted syndrome.
Journal of Dermatological Case Reports · 2013 · 3 citations · open access
Olmsted syndrome
AbstractBACKGROUND: Olmsted syndrome is a rare keratinization disorder characterized by a combination of periorificial keratotic plaques and bilateral palmoplantar transgredient keratoderma. Other clinical manifestations include diffuse alopecia, leukokeratosis of the oral mucosa, onychodystrophy, hyperkeratotic linear streaks, follicular hyperkeratosis and constriction of digits. MAIN OBSERVATIONS: We report a case of Olmsted syndrome in a 5-year-old male presented by mutilating palmoplantar keratoderma, perioral keratoses and linear hyperkeratotic lower limb plaques. CONCLUSIONS: Olmsted syndrome is a rare genodermatosis with only 43 cases reported so far. We present another case of the disease.
Clinical and Experimental Dermatology · 2024 · 2 citations
A case of Olmsted syndrome with dramatic response to erlotinib
AbstractA 63-year-old man with Olmsted syndrome, which was causing him severe pain and had been impairing his quality of life since birth, was treated with erlotinib 100 mg once daily. This led to a dramatic improvement in both his pain and quality of life. Owing to side-effects, the dose was reduced to 100 mg three times a week, which has maintained efficacy. Side-effects are now minimal.
Table 2_Pathogenesis and management of TRPV3-related Olmsted syndrome.docx
AbstractOlmsted syndrome is characterized by symmetrically distributed, destructive, inflammatory palmoplantar keratoderma with periorificial keratotic plaques, most commonly due to gain-of-function mutations in the transient receptor potential vanilloid 3 (TRPV3) gene, which involves multiple pathological functions of the skin, such as hyperkeratosis, dermatitis, hair loss, itching, and pain. Recent studies suggest that mutations of TRPV3 located in different structural domains lead to cases of varying severity, suggesting a potential genotype-phenotype correlation resulting from TRPV3 gene mutations. This paper reviews the genetics and pathogenesis of Olmsted syndrome, as well as the potential management and treatment. This review will lay a foundation for further developing the individualized treatment for TRPV3-related Olmsted syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
